WX ATU Co., Ltd. Files IPO Prospectus: A Global Full-Service CDMO Leader in Cell and Gene Therapy

WuXi ATU

Full Company Name：WuXi ATU

Booth Number: A107-2

WuXi ATUis a company focused on cell and gene therapies (A Contract Development and Manufacturing Organization (CDMO) for Cell and Gene Therapy (CGT), featuring an open technology platform that encompasses plasmids, viral vectors, cell therapies, and various innovative therapeutic services. With proven expertise and a successful track record in regulatory filings across the United States, the European Union, and China, it provides efficient and reliable end-to-end support for drug development to global innovative pharmaceutical companies.

WuXi ATU possesses a mature, integrated drugCMC Development and cGMP Manufacturing Capabilities: Providing Global Clients with Efficient, Compliant, and Scalable Solutions from DNA to CommercializationCDMO Services, accelerating the clinical development and commercialization of innovative therapies. As a strategic partner for cell and gene therapy clients, WuXi ATU has facilitated marketing authorization approval for one project in mainland China and Macau, China, and is the only CDMO to have undergone an on-site inspection coupled with review by the Center for Drug Evaluation (CDE). Furthermore, WuXi ATU has supported multiple projects in obtaining clinical trial approvals and managing changes during clinical trials, with approvals granted in countries including China, the United States, Singapore, South Korea, Australia, and Germany.

WuXi ATU has always adhered to the principle of equal emphasis on innovation and quality, striving to provide customers with excellent services and high-quality products. We firmly believe that only through continuous technological innovation and rigorous quality control can we drive the sustained development and progress of cell and gene therapies. WuXi ATU has established a system compliant with U.S.Quality systems and operational systems that comply with the regulatory standards of the FDA, the EU’s EMA, China’s NMPA, and other major regulatory authorities. Currently approved by Chinese drug regulatory authoritiesCGTOn-site inspection for the new drug launch and three EU QP inspections, with the FDA on-site inspection completed in 2025.

We look forward to meeting you at the upcoming exhibition, engaging in in-depth discussions, exploring future collaboration opportunities, and working together to create a brighter tomorrow!

Contact Us:

WuXi ATU WX ATU Co., Ltd.

Phone：+86(510)8858 3666

Email：wxatu@i-incubator.com

Address: Huishan Avenue, Wuxi Huishan Economic Development Zone, Jiangsu Province1719-6No. 1, 1st FloorADistrict

To drive technological breakthroughs, industrial integration, policy alignment, and international cooperation in China’s cell and gene therapy (CGT) sector, and to propel the Chinese CGT industry to the forefront of global competition, the China Society for Gene and Cell Therapy (CSGCT) Conference was established.

Leveraging its close ties with the ASGCT (American Society of Gene & Cell Therapy), the 2025 CSGCT Annual Meeting will bring together allGlobal Excellence in Sciencehomes, clinical experts, multinational pharmaceutical companies, and overseas investment institutions, bringing the most in the global field of cell and gene therapyCutting-edge research advances, technologies and applications, market access information, high-quality collaboration opportunities, and overseas investors and investment needsSeeking Partnerships: Building a Platform for In-Depth Exchange and Cooperation Between China’s Cell and Gene Therapy Industry and the Global Value Chain.

The conference closely addressed the industry’s hotspots, pain points, and bottlenecks, featuring1 Main Forum + 15 High-End Sub-forums, coveringLatest Advances in Global Gene Therapy, Immune Cell Therapy, In Vivo CAR-T, Adult Stem Cells and Exosomes, iPSC-Derived Cell Therapies, Small Nucleic Acid Drugs, Gene Editing, Oncolytic Viruses, and Tumor Vaccines, as well as CMC and Testing, AI-Driven Drug Discovery, Registration and Regulation, and Investment, Financing, and Business Development MatchmakingWaitComprehensive Coverage of the Entire Industry Chain.

2025 2nd China Society for Gene and Cell Therapy (CSGCT) Conference

September 12–13, 2025

Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]

For more details, scan the QR code to visit the official conference website.